Repligen (NASDAQ:RGEN) Shares Up 10.1% – Should You Buy?

Repligen Corporation (NASDAQ:RGEN) shot up 10.1% during mid-day trading on Wednesday . The stock traded as high as $139.50 and last traded at $139.1240. Approximately 445,146 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 956,611 shares. The stock had previously closed at $126.37.

Analysts Set New Price Targets

A number of research firms recently issued reports on RGEN. Roth Mkm started coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective for the company. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Canaccord Genuity Group lowered their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Finally, Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Stock Performance

The company has a market cap of $7.86 billion, a P/E ratio of 154.66, a PEG ratio of 2.44 and a beta of 1.09. The company has a 50 day moving average price of $121.94 and a 200-day moving average price of $135.79. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities analysts expect that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC bought a new stake in Repligen during the third quarter worth approximately $368,387,000. Opti Capital Management LP bought a new position in shares of Repligen in the fourth quarter valued at $2,399,209,000. Maverick Capital Ltd. acquired a new stake in shares of Repligen during the 1st quarter valued at $178,946,000. Wasatch Advisors LP bought a new stake in shares of Repligen during the 1st quarter worth $146,513,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Repligen during the 4th quarter worth $199,176,000. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.